慢性阿片类药物使用与肝硬化患者肠道菌群改变相关并预测再入院
研究纳入200例肝硬化住院患者前瞻性随访6个月,另比较72例慢性阿片使用与72例年龄/MELD/既往HE匹配的对照。慢性阿片使用与全因再入院(69% vs 48%,P=0.008)及内毒素血症、菌群失调相关,但与HE相关再入院无显著差异(30% vs 41%,P=0.30)。
要点
- 慢性阿片使用与肝硬化患者全因再入院率升高相关(69% vs 48%,P=0.008)。
- 阿片使用与HE相关再入院无显著差异(30% vs 41%,P=0.30)。
- 阿片使用组内毒素血症和IL-6升高,菌群失调以自体菌群及拟杆菌科相对丰度降低为特征。
核心结论
- 肝硬化患者慢性阿片使用与内毒素血症增加、菌群失调及全因再入院增多相关。
研究设计与样本
- 队列1为200例肝硬化住院患者(使用/不使用阿片),前瞻性随访住院期间及出院后6个月,比较再入院。
- 队列2为72例慢性阿片使用的肝硬化患者,与72例年龄/MELD/既往HE匹配的非阿片使用者比较粪便菌群组成、预测功能、内毒素血症及全身炎症。
主要发现
- 队列1中,144例6个月时存活患者中82例再入院;阿片使用者全因再入院显著更高(69% vs 48%,P=0.008),HE相关再入院无显著差异(30% vs 41%,P=0.30)。
- 回归分析中,阿片治疗和女性性别可独立于MELD评分和既往HE预测再入院。
- 队列2中阿片组存在显著菌群失调,尤其HE+阿片患者自体菌群和拟杆菌科相对丰度降低。
- PiCRUST显示阿片使用者芳香族氨基酸和内毒素产生最高。
- 阿片使用者内毒素血症和IL-6更高,但IL-17无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid use is epidemic in cirrhosis, which could precipitate hepatic encephalopathy (HE) potentially through gut dysbiosis and inflammation. AIM: To define the effect of opioids on readmissions and on gut microbiota composition and functionality. METHODS: Cohort 1 had 200 cirrhotic in-patients (with/without opioid use) followed prospectively through the index hospitalisation and 6 months post discharge. Readmissions (HE-related/unrelated) were compared between patients discharged on opioids compared to the rest, including using a multi-variable analysis. Cohort 2 consisted of 72 cirrhotics on chronic opioids who were age/model for end-stage liver disease (MELD) and prior HE-balanced with 72 cirrhotics not on opioids. Stool microbiota composition (multi-tagged sequencing), predicted functionality (PiCRUST), endotoxemia and systemic inflammation (IL-6, IL-17) were compared. RESULTS: Cohort 1: Chronic opioid use was statistically similar between those admitted with/without HE, and was judged to be an HE precipitant in <5% of cases during the index hospitalisation. Of the 144 patients alive at 6 months, 82 were readmitted. The opioid users had a significantly higher all cause (69% vs. 48%, P = 0.008), but not HE-related readmissions (30% vs. 41%, P = 0.30). On regression, opioid therapy and female gender were predictive of readmission independent of MELD score and previous HE. Cohort 2: Significant dysbiosis was noted in the opioid cohort, especially in HE+opioid patients with lower autochthonous taxa and Bacteroidaceae relative abundance. PiCRUST showed highest aromatic amino acid and endotoxin production in opioid users. Opioid users also had higher endotoxemia and IL-6 but not IL-17. CONCLUSION: Chronic opioid use in cirrhosis is associated with increased endotoxemia, dysbiosis and all-cause readmissions.
引用
- Acharya C, Betrapally NS, Gillevet PM, et al. Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment Pharmacol Ther. 2016. PMID: 27868217. doi:10.1111/apt.13858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。